A Randomized, Investigator‐Blinded, Split‐Face, Controlled Trial Assessing Efficacy and Satisfaction of CE Ferulic Serum Following Nonablative Fractional Fraxel Laser Treatment for Photoaging Skin in Chinese Population
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70251 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Xiaolei Qin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Deyue Clinic, Shenzhen, China. Hauptthemen laut MEDLINE: Skin Aging, Coumaric Acids, Cosmetic Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: L'Oreal Dermatological Beauty China, SkinCeuticals..
Abstract (Originalsprache)
Background
Following Nonablative fractional Fraxel laser (NAFL), a well‐established treatment for skin rejuvenation, immediate post‐procedural care is essential to address any potential complications and accelerate the healing process.
Aims
To evaluate the efficacy and patient satisfaction of a topical skincare regimen containing vitamin C, vitamin E, and ferulic acid—CE Ferulic serum (CEF) following NAFL treatment in the Chinese population.
Methods
In this randomized, investigator‐blinded, split‐face, controlled trial, patients with mild‐to‐moderate facial photodamage were randomized to receive CEF treatment on one side of the face and normal saline (NS) on the other side immediately after the NAFL procedure and daily during the 7‐day follow‐up. The primary endpoint was the change from baseline in erythema score on Day 7, with key secondary endpoints including changes from baseline in erythema index (EI), melanin index (MI), transepidermal water loss, skin hydration, skin sebum content, scabbing, edema, overall patient satisfaction, and post‐procedure pain.
Results
In total, 50 patients (female 45/50) were enrolled in this study, with a mean age of 31.6 years. The mean change from baseline in erythema score was significantly lower on the CEF side than on the NS side on Day 7 post‐NAFL treatment (0.04 ± 0.40 vs. 0.18 ± 0.48, p = 0.011). The CEF side also exhibited improved changes in EI, MI, and skin hydration, as well as higher overall satisfaction and less pain compared with the NS side.
Conclusions
Applying CEF after NAFL treatment reduced erythema progression, maintained skin hydration, and promoted the healing process compared with NS. Trial Registration Chinese Clinical Trial Registry: ChiCTR2300069246
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Deyue Clinic, Shenzhen, China.
- Dexi Cosmetic Clinic, Deyi Skin Institution, Xi'an, China.
Förderung
- L'Oreal Dermatological Beauty China, SkinCeuticals.
Zitieren
APA
Qin, X., Zhai, J., Zhou, C., Wang, Y., Chen, M., Zhu, L., Shi, Q., Chen, W., Zhang, L., Luo, X., & Li, K. (2025). A Randomized, Investigator‐Blinded, Split‐Face, Controlled Trial Assessing Efficacy and Satisfaction of CE Ferulic Serum Following Nonablative Fractional Fraxel Laser Treatment for Photoaging Skin in Chinese Population. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70251
Vancouver
Qin X, Zhai J, Zhou C, Wang Y, Chen M, Zhu L, et al. A Randomized, Investigator‐Blinded, Split‐Face, Controlled Trial Assessing Efficacy and Satisfaction of CE Ferulic Serum Following Nonablative Fractional Fraxel Laser Treatment for Photoaging Skin in Chinese Population. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70251
BibTeX
@article{Qin2025,
author = {Qin, Xiaolei and Zhai, Jinlong and Zhou, Chenxi and Wang, Yanmei and Chen, Mengjiao and Zhu, Lin and Shi, Qi and Chen, Weiliang and Zhang, Liyuan and Luo, Xiao and Li, Kai},
title = {A Randomized, Investigator‐Blinded, Split‐Face, Controlled Trial Assessing Efficacy and Satisfaction of CE Ferulic Serum Following Nonablative Fractional Fraxel Laser Treatment for Photoaging Skin in Chinese Population},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70251}
}
EUVIMED